Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Therapeutic Advances in Drug Safety|August 13, 2014
Safety of long-acting beta agonists and inhaled corticosteroids in children and adolescents with asthmaYing Xia, Christina M L Kelton, Liang Xue, et al.
Therapeutic Advances in Neurological Disorders|March 18, 2025
Evaluating natalizumab first-line and later-line use in multiple sclerosis: a US claims database analysisRobin L Avila, Nicole S Croteau, Fei Tang, et al.
Journal of Medical Economics|June 21, 2026
Natalizumab is associated with improved relapse outcomes and lower healthcare utilization versus ocrelizumab in treatment-naïve people with multiple sclerosisJeffrey Kaplan, Dana Beenstock, Martin Belkin, et al.
Applied Health Economics and Health Policy|February 20, 2014
Firm- and drug-specific patterns of generic drug payments by US medicaid programs: 1991-2008Christina M L Kelton, Lenisa V Chang, Jeff J Guo, et al.
Circulation. Cardiovascular Quality and Outcomes|October 4, 2024
Long-Term Clinical Outcomes Following the WATCHMAN Device Use in Medicare BeneficiariesEmily P Zeitler, Boyang Bian, Robert I Griffiths, et al.
Drugs - Real World Outcomes|May 29, 2025
Real-World Treatment Outcomes in Black, Hispanic, Asian, and White Patients with Multiple Sclerosis Treated with NatalizumabKaren Blitz-Shabbir, Aimee M Banks, Hina Garg, et al.
Neurology|February 20, 2025
Real-world Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates (P4-6.005)Sophia Woodson, Edward Gettings, Chu-Yueh Guo, et al.
Neurology and Therapy|June 16, 2025
Comparative Effectiveness of Fumarates Versus Sphingosine-1-Phosphate Receptor Modulators in Black Patients with Multiple SclerosisSophia Woodson, Edward J Gettings, Chu-Yueh Guo, et al.
Neurology and Therapy|June 16, 2025
Real-World Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates in the USASophia Woodson, Edward J Gettings, Chu-Yueh Guo, et al.
Advances in Therapy|February 18, 2026
Comparative Effectiveness and Risk of Severe Infection in Adult Patients With MS Treated With Diroximel Fumarate Versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims AnalysisAhmed Z Obeidat, Michelle Betz, Rebecca Straus Farber, et al.
Pageof 2